{"id":839022,"date":"2025-04-17T21:11:02","date_gmt":"2025-04-18T01:11:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/"},"modified":"2025-04-17T21:11:02","modified_gmt":"2025-04-18T01:11:02","slug":"kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/","title":{"rendered":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials"},"content":{"rendered":"

<\/p>\n

KILL <\/b>Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials<\/b><\/p>\n

\n\u00a0\n<\/p>\n

–(BUSINESS WIRE<\/a>)–
\nAditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 \u201cAditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\u201d be killed.\n<\/p>\n

\nThe release was issued in error by Aditxt, Inc.\n<\/p>\n

\nA replacement release will not be issued at this time.\n<\/p>\n

Aditxt, Inc.<\/span>\u00a0
\n<\/b>
Corporate Communications\u00a0
\n
Jeff Ramson, PCG Advisory, Inc.\u00a0
\n
T: 646-863-6893\u00a0
\n
contactus@aditxt.com<\/a><\/p>\n

KEYWORDS:<\/b> Europe United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health FDA Diabetes Health Technology Genetics Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials \u00a0 –(BUSINESS WIRE)– Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 \u201cAditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\u201d be killed. The release was issued in error by Aditxt, Inc. A replacement release will not be issued at this time. Aditxt, Inc.\u00a0 Corporate Communications\u00a0 Jeff Ramson, PCG Advisory, Inc.\u00a0 T: 646-863-6893\u00a0 contactus@aditxt.com KEYWORDS: Europe United States North America California INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health … <\/p>\n

Continue reading “KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-839022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials \u00a0 –(BUSINESS WIRE)– Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 \u201cAditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\u201d be killed. The release was issued in error by Aditxt, Inc. A replacement release will not be issued at this time. Aditxt, Inc.\u00a0 Corporate Communications\u00a0 Jeff Ramson, PCG Advisory, Inc.\u00a0 T: 646-863-6893\u00a0 contactus@aditxt.com KEYWORDS: Europe United States North America California INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health … Continue reading "KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-18T01:11:02+00:00\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\",\"datePublished\":\"2025-04-18T01:11:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/\"},\"wordCount\":156,\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/\",\"name\":\"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"datePublished\":\"2025-04-18T01:11:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/","og_locale":"en_US","og_type":"article","og_title":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Market Newsdesk","og_description":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials \u00a0 –(BUSINESS WIRE)– Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 \u201cAditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\u201d be killed. The release was issued in error by Aditxt, Inc. A replacement release will not be issued at this time. Aditxt, Inc.\u00a0 Corporate Communications\u00a0 Jeff Ramson, PCG Advisory, Inc.\u00a0 T: 646-863-6893\u00a0 contactus@aditxt.com KEYWORDS: Europe United States North America California INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health … Continue reading \"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-18T01:11:02+00:00","author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials","datePublished":"2025-04-18T01:11:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/"},"wordCount":156,"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/","name":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"datePublished":"2025-04-18T01:11:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kill-aditxt-subsidiary-adimune-announces-positive-results-from-mayo-clinic-pre-clinical-studies-to-support-fda-and-european-regulatory-submissions-for-type-1-diabetes-psoriasis-and-stiff-person-synd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=839022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/839022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=839022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=839022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=839022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}